Imagion Biosystems Ltd. · ASX:IBX
Imagion Biosystems — Shareholder Meeting (May 2021)
14 slides from Imagion Biosystems's shareholder meeting presentation, May 28, 2021
Slide 1: Imagion Biosystems Limited (ASX:IBX) - AGM Presentation, 28th May 2021
For personal use only Imagion Biosystems Limited (ASX:IBX) - AGM PRESENTATION 28TH MAY 2021 www.imagionbiosystems.com
Slide 2: Imagion Biosystems – at a glance
Imagion Biosystems – at a glance New medical imaging technologies for the early detection of cancer For personal use only Imagion Biosystems ASX:IBX • Innovative medical imaging using magnetic nanoparticles to identify and Australian Medical Device Company developing stage cancer early bio-safe medi
Slide 3: MagSense® - A new approach to medical imaging
MagSense® - A new approach to medical imaging Imagion’s technology will transform cancer diagnosis For personal use only • Non-invasive – a safe and non-surgical solution to detect cancer • No radioactivity - uses bio-safe magnetic nanoparticles to “tag” cancer cells • Platform technology – can be u
Slide 4: Clear unmet medical need
Clear unmet medical need 50 years since last new imaging technology was introduced For personal use only X-RAY ULTRASOUND MAGNETIC RESONANCE (MRI) COMPUTED TOMOGRAPHY POSITRON EMISSION (MAMMOGRAPHY) 1956 1971 (CT) TOMOGRAPHY (PET) 1913 1972 1973 • Best for imaging soft tissue • Best used for finding
Slide 5: Broad Commercial Applicability
Broad Commercial Applicability May be used for many types of cancer and at multiple stages of diagnosis For personal use only MAGSENSE ® NANOPARTICLES MULTIPLE CLINICAL TARGETS • Are bio-functionalized to ensure high specificity for targeting different types of cancers, or other diseases. Brain canc
Slide 6: 2020-2021 Key Achievements
For personal use only 2020-2021 Key Achievements MagSense® enters the clinic Technology pipeline advancements Corporate Milestones • HREC approval for Phase I • University of Sydney research • $14.8 million funds raised study in Australia demonstrates utility of IBX • $2.2 million R&D Tax Refund • C
Slide 7: Study Update
Study Update A first-in-human study of a targeted MagSense® imaging agent For personal use only 01 • First Patient enrolled PHASE I • Multiple sites actively screening patients STUDY • Study aims to assess safety, tolerability, and potential effectiveness of the MagSense® imaging agent 02 • Added Cl
Slide 8: A platform for growth
A platform for growth Significant potential opportunities in biomedical applications of magnetic nanoparticles as results develop For personal use only CANCER SCREENING Magnetic nanoparticles are used to collect/separate tumor cells and cancer DNA from blood • Breast Cancer • Brain Cancer DIAGNOSTIC
Slide 9: Pre-Clinical Initiatives
Pre-Clinical Initiatives Expanding MagSense® technology towards the diagnosis of other important cancers For personal use only Prostate Cancer Brain Cancer • IBX received $50,000 CSIRO Federal • Collaboration with Patrys Limited (ASX.PAB) Government Grant for prostate cancer project. • Preclinical r
Slide 10: A Path to Growth and Value
A Path to Growth and Value Strategic plan provides path to future products and shareholder value For personal use only STAGING TUMOR MRI TREATMENT DOCTORS DETECTION & BREAST DETECTION CONTRAST MONITORING OFFICE THERAPY CANCER Reduce unnecessary Breast, prostate, Safer alternative to Monitor tumor Ha
Slide 11: Capital Structure
Capital Structure Well funded throughout 2021 into 2022 For personal use only • 2021 cash flows funded by cash Ordinary shares on issue 1,041 million reserves, exercise of listed options Listed and unlisted options 353 million and R&D tax incentive (26 May 2021) • Increasing cash inflows from exerci
Slide 12: Backed by strong industry and clinical experience
For personal use only Backed by strong industry and clinical experience BOARD OF DIRECTORS SCIENTIFIC ADVISORS DR JOHN HAZLE PROF LISA HORVARTH DR PAUL GRINT ROBERT PROULX MICHAEL HARSH JOVANKA NAUMOSKA MD Anderson Cancer Chris O’Brien Lifehouse Cardea Bio Chairman & CEO Non-Exec Director Non-Exec D
Slide 13: Disclaimer
DISCLAIMER This investor presentation (Presentation) has been prepared by Imagion Biosystems Limited (Imagion or the Company). This presentation does not constitute or form part of, and should not be construed as, an offer, solicitation or invitation to subscribe for, underwrite or otherwise acquire
Slide 14: Contact
For personal use only Contact: www.imagionbiosystems.com info@imagionbio.com ASX: IBX